Zoya Demidenko: Scholar in Cancer Biology
Zoya Demidenko is a recognized scholar affiliated with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the National Institutes of Health and New York Medical College, developing a robust background in clinical investigation.
Her scientific work encompasses several key domains, among them the PI3K/AKT/mTOR signaling cascade, cellular cycle regulation, biological aging, and malignancy science. To date, she has written more than 46 scientific publications, which have received upwards of 4,100 references a reflection to the impact of her research.
One of her most notable discoveries lies in understanding the processes of cellular senescence. Her studies revealed that when the cell cycle is blocked yet cellular growth persists, cells undergo senescence. Importantly, Zoya Demidenko demonstrated that this transition is controlled with drugs using agents such as rapamycin.
Zoya Demidenko has additionally added considerably to oncological therapy investigation, notably in the domain of selective cell protection a approach designed to safeguarding non-cancerous cells from anticancer drugs whilst leaving malignant cells susceptible. This method carries considerable hope for lowering the adverse effects of cancer treatment.
Throughout her scientific life, Demidenko has partnered with prominent researchers internationally, among them Dr. Mikhail Blagosklonny. Her publications can be found in prestigious publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko is recognized as a widely cited figure in modern biomedical science, whose findings keep to guide our knowledge of how biological cells grow old, interact with therapy, and the ways in which malignant disease may be more effectively combated.
https://www.tandfonline.com/doi/abs/10.4161/cbt.4.4.1702